New anticancer drug: the first oral drug for macular degeneration

Kananji Pharmaceutical Technology (Shanghai) Co., Ltd recently announced that the company has submitted the clinical research application for wet age-related macular degeneration of CM082 new anticancer drug to Shanghai food and drug administration, which has been accepted by the Bureau on January 31, and recently reported to the National Drug Review Center for formal review CM082 is a new oral small molecule targeted anticancer drug designed by Dr Liang Congxin, chief scientist of kananji company Its goal is to target the listed targeted anticancer drug sunitinib of Pfizer company, retain its efficacy but significantly reduce its toxicity Based on the extremely low toxicity of CM082 in recent two years, FDA approved the clinical trial of wet age-related macular degeneration, which was launched in November 2012 According to Dr Liang Congxin, no toxic and side effects were observed in the first few patients in the past two months, and all of them showed continuous vision improvement soon after administration, which was better than expected The clinical research application for macular degeneration indication submitted by kananji is the second clinical research application for the same new drug.